Skip to main content

Table 2 Treatment efficacy of anakinra and canakinumab in patients with MWS

From: Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

IL-1 inhibitor Anakinra cohort (n= 12) Canakinumab cohort (n= 14)
  Baseline Short-term end pointa Comparison short-term end point, baseline Long-term end pointb Comparison long-term end point, baseline Baseline Short-term end pointa Com-parison short-term end point, baseline Long-term end pointb Com-parison long-term end point, baseline
Disease activity score (MWS-DAS)
Mean MWS-DAS (stdv) 13 (2.2) 3 (1.0) 0.0005 4 (3.2) 0.0005 6 (1.9) 3 (1.8) 0.002 2 (1.3) 0.0002
Inflammatory markers
Mean ESR in mm/h (stdv) 32 (17) 13 (16) 0.02 10 (5) 0.0005 24 (9.8) 11.9 (4.6) <0.0001 8.4 (4.8) <0.0001
Elevated ESR (%)
(>22 mm/h)
9 (75) 1 (8) - 1 (8) - 9 (64) 0   1 (7)  
Mean CRP in mg/dl (stdv) 2.1 (1.3) 0.9 (1.9) 0.09 NS 0.4 (0.5) 0.0005 2.3 (2.1) 0.1 (0.1) 0.001 0.2 (0.3) 0.001
Elevated CRP (%)
(>0.5 mg/dl)
11 (92) 4 (33) - 3 (25) - 12 (86) 0 - 1 (7) -
Mean SAA in mg/L (stdv) 36.5 (26.1) 27.5 (70.5) 0.67 NS 6.6 (5.2) 0.001 88.4 (185.1) 3.4 (3.8) 0.01 4.50 (5.8) 0.11 NS
Elevated SAA (%)
(>10 mg/L)
11 (92) 4 (33) - 3 (25) - 9 (64) 1 (7) - 1 (7) -
Mean S100A12 in ng/ml (stdv) 240 (172)
(11/12)
142 (57)
(11/12)
0.05 273 (330)
(11/12)
0.70 NS 284.1
(255.5)
73.4
(51.4)
0.01 76.4
(44.5)
0.01
Elevated S100A12 (%)
(>130 ng/ml)
6/11 (55) 6/11 (55) - 5/11 (45) - 10 (71) 1 (7) - 2 (14) -
Remission (MWS-DAS ≤5 plus normal CRP and SAA)
Patients in remission (%) NA 8 (67)   9 (75)   NA 13 (93)   13 (93)  
  1. Stdv, standard deviation. aShort-term end point was 14 days for anakinra and 8 days for canakinumab, based on the specific pharmacokinetic features of each drug. bMedian long-term end point was 12 (5 to 14) months for anakinra and 11 (6 to 15) months for canakinumab.